ReviewFrontiers in radiology2025
Intra-tumoral susceptibility signals in brain gliomas: where do we stand?
Review in Frontiers in radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nowadays, the genetic and biomolecular profile of neoplasms-related with their biological behaviour-have become a key issue in oncology, as they influence many aspects of both diagnosis and treatment. In the neuro-oncology field, neuroradiological research has recently explored the potential of non-invasively predicting the molecular phenotype of primary brain neoplasms, particularly gliomas, based on magnetic resonance imaging (MRI), using both conventional and advanced imaging techniques. Among these, diffusion-weighted imaging (DWI), perfusion-weighted imaging (PWI), MR spectroscopy (MRS) and susceptibility-weighted imaging (SWI) and have been used to explore various aspects of glioma biology, including predicting treatment response and understanding treatment-related changes during follow-up imaging. Recently, intratumoral susceptibility signals (ITSSs)-visible on SWI-have been recognised as an important new imaging tool in the evaluation of brain gliomas, as they offer a fast and simple non-invasive window into their microenvironment. These intratumoral hypointensities reflect critical pathological features such as microhemorrhages, calcifications, necrosis and vascularization. Therefore, ITSSs can provide neuroradiologists with more biological information for glioma differential diagnosis, grading and subtype differentiation, providing significant clinical support in prognosis assessment, therapeutic management and treatment response evaluation. This review summarizes recent advances in ITSS applications in glioma assessment, emphasizing both its potential and limitations while referencing key studies in the field.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.